Incannex Healthcare (IXHL) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Incannex Healthcare in September 2026.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
About This Stock
INCANNEX HEALTHCARE INC
IXHL
Current Price
$3.26
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
IXHL
Market Cap
N/A
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.